Involym 408 mg (Lymecycline) – Acne & Bacterial Infection Treatment

Buy Involym 408 mg from Tabexports – Global Medicine Exporter

Involym 408 mg (Lymecycline) is a tetracycline-class antibiotic primarily used to treat moderate to severe acne and bacterial infections. The active ingredient Lymecycline 408 mg works by inhibiting the growth of bacteria responsible for skin infections, helping reduce inflammation, pimples, and acne breakouts.

Tabexports supplies Involym 408 mg capsules for international pharmaceutical markets, offering bulk export, wholesale supply, and reliable global shipping to countries including United States, United Kingdom, Australia, France, Thailand, and worldwide.

Active Ingredient

• Lymecycline 408 mg

Lymecycline is a broad-spectrum antibiotic belonging to the tetracycline family, commonly prescribed for acne vulgaris and bacterial infections.

Medical Uses

✔ Treatment of moderate to severe acne
✔ Management of bacterial skin infections
✔ Reduction of acne inflammation and pimples
✔ Treatment support for rosacea-related infections
✔ Control of bacterial growth on the skin

⚠ Use only under the supervision of a healthcare professional.

Key Benefits

• Effective acne treatment antibiotic

• Reduces bacterial infection and inflammation

• Helps improve skin appearance and clarity

• Widely used by dermatologists worldwide

• Convenient once-daily dosage in many cases

Directions for Use

1. Take Involym 408 mg capsule orally with water.

2. Usually taken once daily or as prescribed by a doctor.

3. Do not exceed the recommended dosage.

4. Complete the full course for effective treatment.

Storage Instructions

• Store below 25°C

• Keep away from moisture and heat

• Keep out of reach of children

Why Choose Tabexports?

🌍 Worldwide pharmaceutical exporter
📦 Bulk medicine supply for distributors and wholesalers
🚚 Reliable international shipping
🏭 High-quality pharmaceutical sourcing
📈 Trusted by pharmacies and healthcare suppliers globally

Tabexports exports Involym 408 mg (Lymecycline) to USA, UK, Australia, France, Thailand, and worldwide pharmaceutical markets.